BioNotebook: Four deal updates, a venture funding round and a milestone fee
This article was originally published in Scrip
TG Therapeutics signs a study partner; Editas completes patent deals; J&J adds two collaborators; Allena raises $25m Series B; and CTI earns Trisenox milestone fee.
You may also be interested in...
Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.